EXACT SCIENCES CORP 4

EVP of Human Resources Sarah Condella had all of her Exact Sciences common stock, 401(k) shares, vested options, and RSUs cancelled or cashed out at the $105.00 per-share merger price in connection with Abbott’s acquisition of Exact Sciences on March 23, 2026.

On March 23, 2026, in connection with the closing of Abbott Laboratories’ acquisition of Exact Sciences Corporation at $105.00 per share in cash, EVP of Human Resources Sarah Condella had all of her equity positions in Exact Sciences effectively cashed out or converted. A new grant of 60,389 shares of common stock (likely merger-related or a conversion/assumption event) is reported as acquired, bringing her direct holdings to 191,891 shares before the merger cash-out. Simultaneously, her 191,891 directly held common shares and 6,368 shares held indirectly in a 401(k) plan were disposed of for cash consideration, as were multiple tranches of vested stock options (21,948 options at a $21.68 strike, 11,700 options at $44.37, 7,790 options at $92.62, and 6,581 options at $98.18), each cancelled in exchange for their intrinsic value based on the $105.00 merger price. In addition, 23,224 RSUs outstanding immediately prior to the effective time were treated under the merger terms (with some RSUs assumed by Abbott, others cancelled for cash), leaving her with zero post-transaction holdings of Exact Sciences common stock, while her ongoing exposure is transitioned into Abbott equity/rights rather than Exact Sciences shares.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118758

Alert Tier

7